Zobrazeno 1 - 10
of 1 205
pro vyhledávání: '"apalutamide"'
Autor:
Karel David, Paul Van Crombrugge, Anne-Marie Van der Biest, Frederiek D’Hondt, Frank Claessens, Alexander Giesen, Steven Joniau, Brigitte Decallonne
Publikováno v:
European Thyroid Journal, Vol 13, Iss 5, Pp 1-5 (2024)
The androgen receptor signaling inhibitor apalutamide is used successfully for the treatment of prostate cancer. An increased risk of hypothyroidism, mostly subclinical, has been reported in the SPARTAN and TITAN trials. We present three cases of sub
Externí odkaz:
https://doaj.org/article/f9fce8ce57794b239a91052f1bdef83f
Autor:
Mario Hassi Roman, Kinga Mate, Pedro De Pablos-Rodriguez, Álvaro Zamora Horcajada, Ana Guijarro Cascales, Ángeles Sanchís Bonet, Antoni Vilaseca, Darío Vázquez-Martul Pazos, Estefanía Linares Espinós, Jesús Muñoz Rodríguez, José Manuel de la Morena Gallego, José Ramón Alemán, Juan Gómez Rivas, Luigi Formisano, Maria J. Juan Fita, Marc Costa Planells, Mario Domínguez Esteban, Meritxell Pérez Márquez, Miguel García Sanz, Nagore García Expósito, Natalia Picola, Pol Servian Vives, Raquel Sopeña Sutil, Miguel A. Climent Durán, Miguel Ramírez Backhaus
Publikováno v:
European Urology Open Science, Vol 70, Iss , Pp 58-63 (2024)
Background and objective: The depth of the prostate-specific antigen (PSA) decline after androgen receptor pathway inhibitor (ARPI) treatment combined with androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer (m
Externí odkaz:
https://doaj.org/article/0fc7ebd364174fe89c2487f7f9fb39f3
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 609-620 (2024)
Abstract Apalutamide is a selective androgen receptor signalling inhibitor that is used in the treatment of prostate cancer. Skin rash is one of the most common adverse events with apalutamide. Although the majority of rash events are grade 1 and 2,
Externí odkaz:
https://doaj.org/article/127c164f6eac4c2a9053f0823c49889d
Autor:
K Ganesh Kadiyala, K. Jagadeesh, Ch. Geetika, I. Lakshmi Lavanya, B. Kanaka Durga, J. Suresh Kumar, Bachina Kiran, B. N. Suresh Varma Dendukuri
Publikováno v:
Proceedings on Engineering Sciences, Vol 6, Iss 3, Pp 1317-1326 (2024)
Molecular docking simulations were conducted to analyze the interactions between eight lead molecules with AR and PSA proteins. The lead molecules included Enzalutamide, Abiraterone, Docetaxel, Apalutamide, Cabazitaxel, Bicalutamide, Curcumin, Galete
Externí odkaz:
https://doaj.org/article/7cd3e08550d54968b81543b4dd43e5e9
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-16 (2024)
Abstract Apalutamide, a novel endocrine therapy agent, has been shown to significantly improve the prognosis of patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, resistance to apalutamide has also been reported, and the und
Externí odkaz:
https://doaj.org/article/6b7f7c2bed924ea0af11073bab9179c2
Autor:
Javier Gil-Lianes, Victoria Amat-Samaranch, Priscila Giavedoni, Antoni Vilaseca, Julián Córdoba Sánchez, Francesc Alamon-Reig, Paola Castillo, Adriana P. Garcia, Mariona Pascal, Cristina Carrera
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
Abstract is missing (Short communication)
Externí odkaz:
https://doaj.org/article/eb6d5e0581b5403998330e7f0fdd0a3d
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 3, Pp 543-550 (2024)
Antiandrogens have been used for the treatment of prostate cancer as a single agent or in combination with hormone deprivation therapy. New generation antiandrogens act like androgen receptor inhibitors (ARIs). Their binding complex blocks the pathwa
Externí odkaz:
https://doaj.org/article/d16ce22b5d594bbc955af0adc657912a
Autor:
Beihe Wang, Jian Pan, Tingwei Zhang, Xudong Ni, Yu Wei, Xiaomeng Li, Bangwei Fang, Xiaoxin Hu, Hualei Gan, Junlong Wu, Hongkai Wang, Dingwei Ye, Yao Zhu
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background The proposed trial is to examine the feasibility of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)-guided cytoreduction plus apalutamide and androgen deprivation therapy (ADT) f
Externí odkaz:
https://doaj.org/article/4ada5a7d195b4eb1a06476185db8e3c3
Publikováno v:
Frontiers in Chemistry, Vol 12 (2024)
Introduction: Prostate cancer (PC) ranks as the second most frequent type of cancer in men and is the fourth largest cause of mortality worldwide. Androgenic hormones such as testosterone and dihydrotestosterone are crucial for the development and pr
Externí odkaz:
https://doaj.org/article/6215e8f7e50a45119e89df595e9cfe5a
Autor:
Julián Córdoba Sánchez, Natalia Picola, Alejo Rodriguez‐Vida, Marc Costa, David Marmolejo Castañeda, Meritxell Pérez Márquez, Jesús Muñoz Rodriguez, J. M. Gaya, Alejandra Bravo, Oscar Buisan, Pol Servian, Jose Francisco Suarez, Mireia Musquera Felip, Maria Jose Ribal Caparrós, Antonio Alcaraz Asensio, Antoni Vilaseca
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 21969-21977 (2023)
Abstract Objective To evaluate the efficacy and safety of apalutamide prostate cancer compared to the pivotal trials patients and to identify the first subsequent therapy in a real‐world setting. Methods The study is prospective and observational b
Externí odkaz:
https://doaj.org/article/80a7c7a4e5bf42c59346f59c54b642d5